Hans M. Schrijver

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Association of interleukin-1 <b>β</b> and interleukin-1 receptor antagonist genes with disease severity in MS

Hans M. Schrijver, J. Bart A. Crusius, Bernard M.J. Uitdehaag et al. · Neurology · 1999 · 134 citations

Interferon (IFN)-β treatment enhances CD95 and interleukin 10 expression but reduces interferon-γ producing T cells in MS patients

M.H.G. Rep, Hans M. Schrijver, Thea van Lopik et al. · Journal of Neuroimmunology · 1999 · 113 citations · Full text

Cytokine, Ms Patients, Autoimmune Disease +15

Correlating nerve conduction studies and clinical outcome measures on carpal tunnel syndrome: lessons from a randomized controlled trial.

Hans M. Schrijver, Annette Gerritsen, R.L.M. Strijers et al. · PubMed · 2005 · 99 citations

Peripheral Nerve Injury, Carpal Tunnel Syndrome, Clinical Outcome Measures +17